Skip to main content

Lab Notes: Jazz agrees to multimillion-dollar drug sale; Lannett takes 'major step' with biosimilar

Jazz has entered into a definitive agreement to sell the rights to one of its drugs in a deal that includes a $53 million upfront payment.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.